586972-65-8

Upstream product

• 62965-10-0 (S)-N-carbobenzoxy-tert-butylleucine 
• 372199-34-3 Cbz-tBu-Gly-NH₂ 

Downstream Products

• 586972-66-9 [1S-(N-hydroxycarbamimidoyl)-2,2-dimethyl-propyl]-carbamic acid benzyl ester 
• 910377-22-9 benzyl [(1S)-2,2-dimethyl-1-(2H-tetrazol-5-yl)propyl]carbamate 
• 586972-67-0 [2,2-dimethyl-1S-(5-phenyl-[1,2,4]oxadiazol-3-yl)-propyl]-carbamic acid benzyl ester 
• 586972-70-5 2R-(2,2-dimethyl-5-oxo-[1,3]dioxolan-4S-yl)-4-methyl-pentanoic acid [2,2-dimethyl-1S-(5-phenyl-[1,2,4]oxadiazol-3-yl)-propyl]-amide 

Relevant academic research and scientific papers

INDAZOLE DERIVATIVES

This invention relates to compounds, pharmaceutical compositions and methods for the treatment of a condition mediated by CB1 receptor activity in a mammalian subject including a human, which comprises administering to a mammal in need of such treatment a

BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS

This invention relates to compounds of the formula (I): or pharmaceutically acceptable salts thereof, wherein: A, B, R1, R2 and R3 are each as described herein, and compositions containing such compounds and the use of suc

METALLOPROTEINASE INHIBITORS

Compounds formula (IA) or (IB); wherein W represents HO(C=0)-, HONH(C=0)- or H(C=O)N(OH)-; X represents -O- or -S-; and R1, R2, and R3 are as defined in the description and claims, are inhibitors of matrix metalloproteinases, in particular MMP9 and/or MMP12.